Table 2.

Summary of 6 case reports of Fournier’s gangrene associated with SGLT2 inhibitor treatment

Reference	Age, sex	SGLT2 inhibitor	Time to onset (weeks)	HbA1c (%)	Renal and hepatic function	Comorbidities	Concurrent drug therapy
Cecilia-Chi et al. [8]	67, male	Dapagliflozin	3	10.8	Unknown	Obesity	Unknown
Kumar et al. [9]	41, male	Empagliflozin	49	11.2	Unknown	Obesity, thrush	Metformin
Omer et al. [10]	60, male	Dapagliflozin	28	Unknown	Unknown	Unknown	Unknown
Onder et al. [11]	64, male	Dapagliflozin	42	7.4	BUN: 17 mmol/L; Cr: 162 μmol/L; ALT: 21 U/L	Obesity	Premixed insulin, vildagliptin, metformin
Ghada et al. [12]	57, male	Empagliflozin	2	Unknown	Unknown	Obesity, peripheral neuropathy, Hashimoto’s hypothyroidism	Glipizide, metformin, linagliptin
Our patient	34, male	Empagliflozin	20	6.5	BUN: 5.7 mmol/L; Cr: 69 μmol/L; ALT: 18 U/L	Obesity	Sitagliptin, glibenclamide

SGLT2 sodium-glucose cotransporter-2, HbA1c glycated hemoglobin, BUN blood urea nitrogen, Cr creatinine, ALT alanine transaminase